Breastfeeding linked with decreased breast cancer recurrence risk
the ONA take:
According to a new Kaiser Permanente study published in the Journal of the National Cancer Institute, women diagnosed with breast cancer who previously breastfed their babies had a 30% overall decreased risk of disease recurrence.
For the study, researchers analyzed data from 1,636 women with breast cancer who completed a questionnaire that included breastfeeding history.
Researchers observed significant benefits between women who had a history of breastfeeding and outcomes of those diagnosed with the luminal A subtype of breast cancer, such as estrogen-receptor positive tumors. Results also showed women who breastfed were 28% less likely to die from the disease.
"Women who breastfeed are more likely to get the luminal A subtype of breast cancer, which is less aggressive, and breastfeeding may set up a molecular environment that makes the tumor more responsive to anti-estrogen therapy," lead author Marilyn L. Kwan, PhD said as a possible explanation of the observed association.
Women diagnosed with breast cancer who previously breastfed their babies had a 30% overall decreased risk of disease recurrence.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|